ProKidney Corp.
Nancy Fuselli has over 30 years of experience in quality assurance and regulatory roles in the pharmaceutical industry. Nancy is currently the Head of Quality Assurance - Operations at ProKidney Corp. Prior to that, they held the position of Executive Director, Quality Assurance at Verve Therapeutics.
From 2015 to 2019, Nancy served as the Director of Quality at Arcturus Therapeutics, where they developed and managed quality and regulatory strategies for mRNA/siRNA treatments. Before that, they were the Director of Quality and Regulatory at Tekmira Pharmaceuticals (now Genevant Sciences) from 2004 to 2015.
Nancy also has experience as a Quality Assurance Manager at Inex Pharmaceuticals from 2002 to 2004 and as a Quality Control intern at Johnson & Johnson (McNeil Consumer Products Company) from 1993 to 1995. Prior to that, they worked at QLT Inc. as a Quality Control professional from 1996 to 2000, where they had direct contact with FDA and Canadian Health authorities for Preapproval Inspections (PAI).
Nancy Fuselli completed their Bachelor of Science degree in Biochemistry at the University of Waterloo in 1995. Nancy then pursued Financial Planning and Services at the British Columbia Institute of Technology, completing their education in 2000. Later, in 2013, Nancy attended Simon Fraser University to further their education in the Writer's Studio program.
This person is not in the org chart
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.